Obesity drugmakers slip after Trump vows to lower weight-loss drug prices

** Shares of weight-loss drugmakers fall premarket after U.S. President Donald Trump said on Thursday that the prices of weight-loss drugs, such as Novo Nordisk's NOVOb.CO Ozempic, would be lowered

** Shares of Eli Lilly LLY.N drop 3.7% to $788.97 in premarket, while U.S.-listed shares of Danish drugmaker Novo Nordisk NVO.O slide 3.8% to $53.97

** Shares of other obesity drug developers Viking Therapeutics VKTX.O down 5.9% at $32.78, while Altimmune ALT.O edges 1% lower to $3.85

** J.P.Morgan says, "we see President Trump’s comments as in line with our expectations for the price negotiation related to Novo’s GLP-1 portfolio"

** YTD, up to last close, LLY up 6.1%, VKTX down 13.7%, ALT down 46%, U.S.-listed Novo down 34.8%